<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205712</url>
  </required_header>
  <id_info>
    <org_study_id>NARSAD - Kids</org_study_id>
    <secondary_id>01-0886</secondary_id>
    <nct_id>NCT00205712</nct_id>
  </id_info>
  <brief_title>Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids</brief_title>
  <official_title>Prevention of NMDA Antagonist-induced Psychosis and Memory Impairment in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for
      emergency sedation in children because it causes deep sedation with minimal respiratory
      depression in comparison to other available agents. However, emergence reactions are an
      important adverse effect of ketamine, characterized by transient changes in cognitive
      function, dissociation and mild schizophrenia-like symptoms. These cognitive and behavioral
      effects are dose-dependently induced by ketamine and other antagonists of the
      N-methyl-D-aspartate (NMDA) glutamate receptor. NMDA receptor hypofunction can disinhibit
      excitatory (cholinergic/glutamatergic) projections in key areas of the brain, and this has
      been proposed to explain key features of schizophrenia. Several treatments that block
      excessive excitatory transmitter release have also been shown to prevent cognitive and
      behavioral effects of ketamine-induced NMDA receptor hypofunction in humans. Alpha-2
      adrenergic agonists, which can presynaptically inhibit acetylcholine release, can prevent
      mild ketamine-induced behavioral and cognitive symptoms in healthy human adults. However,
      this prevention strategy has not been evaluated in children. Children currently receive
      clinically-indicated treatment with the NMDA antagonist, ketamine, and this age group is an
      important target for pharmacological strategies aimed at the prevention of schizophrenia.
      This application proposes a double-blind, placebo-controlled, randomized trial to test the
      safety and effectiveness of dexmedetomidine, an FDA approved alpha-2 adrenergic agonist, in
      preventing ketamine-induced mental symptoms in children. Planned primary analyses will
      evaluate effects of the hypothesized prevention treatment on clinical and cognitive variables
      using analysis of variance (ANOVA). The proposed experiments are relevant to future
      prevention trials for individuals at risk for schizophrenia, and to preventing adverse
      effects of NMDA antagonist anesthetic agents (ketamine, nitrous oxide).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will be conducted using existing dedicated clinical and research space in
      St. Louis Children's Hospital's Emergency Department, Pediatric Clinical Research Center
      (PCRC), and Orthopedic Clinic. This project has 3 major aims and 1 exploratory aim addressed
      by a prospective randomized blinded placebo controlled drug trial to test whether a
      pharmacological strategy can prevent NMDA receptor hypofunction-induced behavioral and
      cognitive dysfunction in pre- and post-pubertal children. Based on previous preclinical and
      clinical research on the effects and blockade of the effects of ketamine and similar
      compounds, the study investigators have carefully selected a dose of the alpha-2 adrenergic
      agonist dexmedetomidine that will permit this study to be conducted with low risk to enrolled
      subjects who are undergoing clinically-indicated ketamine sedation for forearm fracture
      reduction.

      General Experimental Design: This project will test the safety and effectiveness of
      dexmedetomidine for preventing ketamine-induced behavioral and cognitive symptoms in healthy
      human children undergoing clinically indicated ketamine sedation for forearm fracture
      reduction.

      Aims 1 and 2 will be addressed by randomized, blinded administration of dexmedetomidine or
      saline placebo to ketamine-sedated subjects to test the efficacy of dexmedetomidine in
      preventing ketamine-induced behavioral and cognitive changes during recovery from sedation.

      Aim 3 will be addressed by comparing between the subjects randomized to receive
      dexmedetomidine or saline placebo measurements of distress and frequency of adverse
      cardiopulmonary effects during sedation, fracture-reduction, and recovery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Psychiatric Ratings Scale (BPRS) Positive Symptom Subscale Score</measure>
    <time_frame>Before Ketamine, During Ketamine</time_frame>
    <description>Participant received behavioral ratings before medication and during medication for the primary analysis comparison. This is an observer-scale with a value range from 0-6 (0=no symptoms 6=worst symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Intensity</measure>
    <time_frame>Before Ketamine, During Ketamine, Post Ketamine and 1 Week Follow up</time_frame>
    <description>Pain intensity was measured on a scale of 1-10 (1=lowest pain intensity, 10=highest pain intensity) in participants before medication, during medication, post medication and 1 week follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Anxiety Rating</measure>
    <time_frame>Before Ketamine, During Ketamine, Post Ketamine, 1 week follow up</time_frame>
    <description>Anxiety was measured on a scale of 1-10 (1=lowest pain intensity, 10=highest pain intensity) in participants before medication, during medication, post medication and 1 week follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Psychoses, Substance-Induced</condition>
  <arm_group>
    <arm_group_label>Ketamine plue saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ketamine without dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine plus dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine infusion plus dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine without dexmedetomidine</description>
    <arm_group_label>Ketamine plue saline</arm_group_label>
    <other_name>Ketanest</other_name>
    <other_name>Ketaset</other_name>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Ketamine plus dexmedetomidine</description>
    <arm_group_label>Ketamine plus dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients presenting to St. Louis Children's Hospital's Emergency Department who require
        reduction of an acute forearm fracture will be recruited for enrollment if they satisfy the
        following:

          1. Age 7-17 years, inclusive;

          2. Are psychiatrically healthy (i.e. have never been under the care of a psychiatrist or
             taken psychiatrically active medications);

          3. Meet American Society of Anesthesiologist (ASA) Class I and II criteria (I=healthy,
             II=chronic disease under good control);

          4. Have had no prior fracture reduction or ketamine administration;

          5. Present for care when research assistants are present (Monday-Friday, 09:00-23:00);
             and

          6. Have a home telephone or ready means of establishing telephone contact.

        All subjects and their parent/guardian will give Washington University Human Studies
        Committee approved written informed assent and consent prior to participation.

        Exclusion Criteria:

          1. Solid food intake 2 hours or less before procedure;

          2. Compromised cardiorespiratory function; central nervous system, hepatic, or renal
             abnormality;

          3. History of psychosis in patient or first degree relative;

          4. Currently taking medications that stimulate or depress mental function, e.g.
             methylphenidate for attention deficit hyperactivity disorder or drugs of abuse;

          5. History of allergy or adverse reaction to alpha-2 adrenoreceptor agonist drugs, e.g.
             clonidine.

        These exclusion criteria relate to contraindications for use of the agents employed in the
        study. Criteria 1, 2, 3 and 4 are current routine practice for ketamine sedations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W. Newcomer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine and Florida Atlantic University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine, Psychiatry Dept.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>October 27, 2009</results_first_submitted>
  <results_first_submitted_qc>March 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2010</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NMDA antagonist-induced psychosis</keyword>
  <keyword>Children</keyword>
  <keyword>Memory Impairment</keyword>
  <keyword>Decreased cognitive function</keyword>
  <keyword>Increased memory impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Shared Paranoid Disorder</mesh_term>
    <mesh_term>Psychoses, Substance-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine Alone</title>
          <description>Ketamine without dexmedetomidine</description>
        </group>
        <group group_id="P2">
          <title>Ketamine Plus Dexmedetomidine</title>
          <description>Ketamine infusion plus dexmedetomidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine Alone</title>
          <description>ketamine without dexmedetomidine</description>
        </group>
        <group group_id="B2">
          <title>Ketamine Plus Dexmedetomidine</title>
          <description>ketamine infusion plus dexmedetomidine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="2.2"/>
                    <measurement group_id="B2" value="10.9" spread="2.4"/>
                    <measurement group_id="B3" value="11" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brief Psychiatric Ratings Scale (BPRS) Positive Symptom Subscale Score</title>
        <description>Participant received behavioral ratings before medication and during medication for the primary analysis comparison. This is an observer-scale with a value range from 0-6 (0=no symptoms 6=worst symptoms)</description>
        <time_frame>Before Ketamine, During Ketamine</time_frame>
        <population>Completers analysis per protocol. Two participants were missing some data at either the before ketamine or during ketamine time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Alone</title>
            <description>ketamine without dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Plus Dexmedetomidine</title>
            <description>ketamine infusion plus dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Ratings Scale (BPRS) Positive Symptom Subscale Score</title>
          <description>Participant received behavioral ratings before medication and during medication for the primary analysis comparison. This is an observer-scale with a value range from 0-6 (0=no symptoms 6=worst symptoms)</description>
          <population>Completers analysis per protocol. Two participants were missing some data at either the before ketamine or during ketamine time point.</population>
          <units>Scale of 0-6</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPRS Positive symptom subscale-before medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPRS Positive symptom subscale-during medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="2.37"/>
                    <measurement group_id="O2" value="1.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Pain Intensity</title>
        <description>Pain intensity was measured on a scale of 1-10 (1=lowest pain intensity, 10=highest pain intensity) in participants before medication, during medication, post medication and 1 week follow up.</description>
        <time_frame>Before Ketamine, During Ketamine, Post Ketamine and 1 Week Follow up</time_frame>
        <population>Completers analysis per protocol. Two participants were missing some data at either the before ketamine or during ketamine time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Alone</title>
            <description>Ketamine without dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Plus Dexmedetomidine</title>
            <description>Ketamine infusion with dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Pain Intensity</title>
          <description>Pain intensity was measured on a scale of 1-10 (1=lowest pain intensity, 10=highest pain intensity) in participants before medication, during medication, post medication and 1 week follow up.</description>
          <population>Completers analysis per protocol. Two participants were missing some data at either the before ketamine or during ketamine time point.</population>
          <units>Scale of 1-10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Pain-Before Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" spread="1.93"/>
                    <measurement group_id="O2" value="4.03" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Pain-Before Cognitive Testing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="1.65"/>
                    <measurement group_id="O2" value="2.89" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Pain-After Cognitive Testing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="1.33"/>
                    <measurement group_id="O2" value="4.08" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Pain-1 Week F/U</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.59"/>
                    <measurement group_id="O2" value="1.76" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Anxiety Rating</title>
        <description>Anxiety was measured on a scale of 1-10 (1=lowest pain intensity, 10=highest pain intensity) in participants before medication, during medication, post medication and 1 week follow up.</description>
        <time_frame>Before Ketamine, During Ketamine, Post Ketamine, 1 week follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine Alone</title>
            <description>Ketamine without dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Ketamine Plus Dexmedetomidine</title>
            <description>Ketamine infusion with dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Anxiety Rating</title>
          <description>Anxiety was measured on a scale of 1-10 (1=lowest pain intensity, 10=highest pain intensity) in participants before medication, during medication, post medication and 1 week follow up.</description>
          <units>Scale of 1-10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Anxiety-Before Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="2.43"/>
                    <measurement group_id="O2" value="5.0" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Anxiety-Before Cogntive Testing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.97"/>
                    <measurement group_id="O2" value="2.53" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Anxiety-After Cognitive Testing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="1.14"/>
                    <measurement group_id="O2" value="3.00" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS Anxiety-1 Week Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.20"/>
                    <measurement group_id="O2" value="2.06" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine Alone</title>
          <description>Ketamine without dexmedetomidine</description>
        </group>
        <group group_id="E2">
          <title>Ketamine Plus Dexmedetomidine</title>
          <description>Ketamine infusion with dexmedetomidine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Trouble Breathing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Difficulty Walking</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Visual Hallucinations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Unpleasant Dreams</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Newcomer, MD</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-3153</phone>
      <email>newcomerj@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

